In animal models and clinical trials, the combination of a CTLA-4 and PD-1/PD-L1 blockade demonstrated a synergistic effect in eliminating cancer cells, leading to improved survival outcomes for cancer patients [115,116]. Here, CD274 is linked to cancer.